Covance forms I&I unit to meet increasing demand for biologics services

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/anyaivanova)
(Image: Getty/anyaivanova)
Covance has formed a global immunology and immunotoxicology (I&I) unit, which will be dedicated to the “innovative and complex” approaches required by biologics, says CRO.

According to the contract research organization (CRO), the initial investment will focus on increasing global capacity by expanding dedicated laboratory space, instrumentation, and scientific and operations teams. Last year, Covance more than doubled its I&I laboratory footprint and staff size.

The new I&I team collates the company’s capabilities in flow cytometry, immunoassays and cell-based assays with its scientific know-how in study design, direction, and operation.

“The strong scientific bench, increased lab capacity and state-of-the art technology of the new I&I group will lead to richer scientific insights and faster cycle times for clients’ biologic programs,”​ said Sue Maynard, a spokesperson for LabCorp, the parent organization of Covance Drug Development.

Additionally, because Covance provides services across the entire drug development spectrum, the I&I team will be able to provide vertical integration with bioanalysis and clinical development services as well as commercialization and central laboratory services, she told us.

The formation of the unit is in response to increasing demand for these services, Maynard said, adding: “While we don’t disclose specific growth rates for these services, biologics is a growing area of drug development, making up just over a third of biopharma’s R&D pipeline.”

Structurally more complex than traditional chemically synthesized drugs, Maynard explained biologics often require more individualized development plans than the toxicology processes for a small molecule.

“So, while Covance has always and will continue to support immunotoxicology endpoints for small molecules, we are building our new I&I group specifically to handle the innovative and complex approaches more typically required by biologics,”​ she said.

Related news

Show more

Related products

show more

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Related suppliers

Follow us

Products

View more

Webinars